Doping in Sports
Research Guide

Testosterone gel administration in older men with mobility limitations increased cardiovascular adverse events, as demonstrated in a clinical trial by Basaria et al. (2010). This included higher rates of events like nonfatal myocardial infarction and stroke. The unique population and small trial size limit broader generalizations but highlight specific risks.

Anabolic-androgenic steroid use is linked to major mood disturbances, irritability, and aggression, posing public health issues for users and others, per Pope (1994). These psychiatric effects occur alongside medical impacts. Evidence stems from observations in athletes employing steroids for performance enhancement.

Athletes often exhibit positive deviance through overconformity to the sport ethic, leading to excessive behaviors like doping, as analyzed by Hughes and Coakley (1991). This overcommitment to norms valuing winning at all costs normalizes rule-breaking. Such patterns explain much athlete deviance in sports contexts.

Performance-enhancing drugs carry risks like increased hemoglobin, hematocrit, and decreased HDL cholesterol, with unknown clinical significance in some cases, according to Fernández-Balsells et al. (2010). Pope et al. (2013) emphasize health dangers often overlooked outside elite athlete contexts. Prevalence extends to non-elite users, amplifying public health concerns.

Low endogenous testosterone levels correlate with higher all-cause and cardiovascular mortality in community studies of men, per Araujo et al. (2011). Heterogeneity across studies ties to cohort differences. This informs understandings of hormonal influences on health relevant to doping contexts.

Overconformity to the sport ethic—prioritizing winning, risk-taking, and performance—fosters doping as positive deviance, as defined by Hughes and Coakley (1991). Athletes internalize these values excessively, viewing doping as aligned with sport norms. This framework explains persistent doping despite anti-doping efforts.